Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy

被引:71
|
作者
Zile, Michael R. [1 ,2 ]
Abraham, William T. [3 ]
Weaver, Fred A. [4 ]
Butter, Christian [5 ]
Ducharme, Anique [6 ]
Halbach, Marcel [7 ]
Klug, Didier [8 ]
Lovett, Eric G. [9 ]
Mueller-Ehmsen, Jochen [10 ]
Schafer, Jill E. [11 ]
Senni, Michele [12 ]
Swarup, Vijay [13 ]
Wachter, Rolf [14 ,15 ]
Little, William C. [16 ]
机构
[1] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA
[2] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA
[3] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
[4] Univ So Calif, Keck Sch Med, Div Vasc Surg & Endovasc Therapy, Los Angeles, CA 90033 USA
[5] Immanuel Heart Ctr Bernau, Med Sch Brandenburg, Dept Cardiol, Bernau, Germany
[6] Univ Montreal, Montreal Heart Inst, Montreal, PQ H3C 3J7, Canada
[7] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany
[8] Univ Hosp, Dept Cardiol A, Lille, France
[9] CVRx Inc, Dept Res, Minneapolis, MN USA
[10] Asklepios Klin Altona, Dept Med, Hamburg, Germany
[11] NAMSA Inc, Dept Stat, Minneapolis, MN USA
[12] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy
[13] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA
[14] Univ Med Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany
[15] German Cardiovasc Res Ctr DZHK, Gottingen, Germany
[16] Univ Mississippi, Div Cardiovasc, Med Ctr, Jackson, MS 39216 USA
关键词
Baroreflex; Heart failure; Resynchronization; Autonomic nervous system; Randomized controlled trial; INHIBITION; SYSTEM;
D O I
10.1002/ejhf.299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsIncreased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex activation therapy, BAT) results in centrally mediated reduction of sympathetic and increase in parasympathetic activity. Because patients treated with cardiac resynchronization therapy (CRT) may have less sympathetic/parasympathetic imbalance, we hypothesized that there would be differences in the response to BAT in patients with CRT vs. those without CRT. Methods and resultsNew York Heart Association (NYHA) Class III patients with an ejection fraction (EF) 35% were randomized (1 : 1) to ongoing guideline-directed medical and device therapy (GDMT, control) or ongoing GDMT plus BAT. Safety endpoint was system-/procedure-related major adverse neurological and cardiovascular events (MANCE). Efficacy endpoints were Minnesota Living with Heart Failure Quality of Life (QoL), 6-min hall walk distance (6MHWD), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and HF hospitalization rate. In this sample, 146 patients were randomized (70 control; 76 BAT) and were 140 activated (45 with CRT and 95 without CRT). MANCE-free rate at 6 months was 100% in CRT and 96% in no-CRT group. At 6 months, in the no-CRT group, QoL score, 6MHWD, LVEF, NT-proBNP and HF hospitalizations were significantly improved in BAT patients compared with controls. Changes in efficacy endpoints in the CRT group favoured BAT; however, the improvements were less than in the no-CRT group and were not statistically different from control. ConclusionsBAT is safe and significantly improved QoL, exercise capacity, NTpro-BNP, EF, and rate of HF hospitalizations in GDMT-treated NYHA Class III HF patients. These effects were most pronounced in patients not treated with CRT.
引用
收藏
页码:1066 / 1074
页数:9
相关论文
共 50 条
  • [1] Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction
    Abraham, William T.
    Zile, Michael R.
    Weaver, Fred A.
    Butter, Christian
    Ducharme, Anique
    Halbach, Marcel
    Klug, Didier
    Lovett, Eric G.
    Mueller-Ehmsen, Jochen
    Schafer, Jill E.
    Senni, Michele
    Swarup, Vijay
    Wachter, Rolf
    Little, William C.
    JACC-HEART FAILURE, 2015, 3 (06) : 487 - 496
  • [2] Baroreflex activation therapy in patients with heart failure and reduced ejection fraction
    Clemencia, David Cordero
    Panadero, Clemencia de Rueda
    Baguda, Javier de Juan
    Bueno, Manuel Gomez
    Robles-Mezcua, Ainhoa
    Alvarez-Garcia, Jesu
    REVISTA ESPANOLA DE CARDIOLOGIA, 2024, 77 (04):
  • [3] Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review
    Molina-Linde, Juan Maximo
    Cordero-Pereda, David
    Banos-Alvarez, Elena
    Rosario-Lozano, Maria Piedad
    Blasco-Amaro, Juan Antonio
    ESC HEART FAILURE, 2023, 10 (05): : 2760 - 2772
  • [4] Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction
    Zile, Michael R.
    Lindenfeld, Joann
    Weaver, Fred A.
    Zannad, Faiez
    Galle, Elizabeth
    Rogers, Tyson
    Abraham, William T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (01) : 1 - 13
  • [5] Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
    Ruddy, Jean M.
    Kroman, Anne
    Baicu, Catalin F.
    Zile, Michael R.
    HEART FAILURE CLINICS, 2024, 20 (01) : 39 - 50
  • [6] Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease
    Halbach, Marcel
    Abraham, William T.
    Butter, Christian
    Ducharme, Anique
    Klug, Didier
    Little, William C.
    Reuter, Hannes
    Schafer, Jill E.
    Senni, Michele
    Swarup, Vijay
    Wachter, Rolf
    Weaver, Fred A.
    Wilks, Seth J.
    Zile, Michael R.
    Mueller-Ehmsen, Jochen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 266 : 187 - 192
  • [7] Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease
    Halbach, M.
    Abraham, W. T.
    Butter, C.
    Ducharme, A.
    Klug, D.
    Little, W. C.
    Lovett, E.
    Schafer, J. E.
    Senni, E.
    Swarup, V.
    Wachter, R.
    Weaver, F. A.
    Zile, M. R.
    Muller-Ehmsen, J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 724 - 725
  • [8] Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review
    Schmidt, Rodrigo
    Rodrigues, Clarissa Garcia
    Schmidt, Kelen Heinrich
    Costa Irigoyen, Maria Claudia
    ESC HEART FAILURE, 2020, 7 (01): : 3 - 14
  • [9] Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction
    Halbach, Marcel
    Hickethier, Tilman
    Madershahian, Navid
    Mueller-Ehmsen, Jochen
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (12) : 1465 - 1469
  • [10] A Case of Cardiac Resynchronization Therapy for Heart Failure with Reduced Ejection Fraction
    Kupchik, Nicole
    Vance, Sarah
    AMERICAN JOURNAL OF NURSING, 2024, 124 (12) : 50 - 52